Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Advanced Proteome Therapeutics Corporation V.APC


Primary Symbol: V.APC.H Alternate Symbol(s):  APTCF

Healthcare Biotechnology
Advanced Proteome Therapeutics Corporation is actively seeking additional funds to advance its core technologies for partnering and other potential revenue streams. It is not engaged in any activity.


TSXV:APC.H - Post by User

Advanced Proteome Therapeutics Corporation > Crystal Ball
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(0)
•••
Comment by FIRE2032on Jun 02, 2022 9:23pm
110 Views
Post# 34728265

RE:Crystal Ball

RE:Crystal Ball

 Now .05 cents...... it didnt even go below 11 cents.  You have not been right all along lol maybe read the news releases....

APTI plans to perform the first in vivo testing of our solubilizing linker in combination with our conjugation technology this spring with data by mid-year.

The tests will be designed to show the contribution of both our conjugation and linker technologies to ADC performance. APTI believes that these studies will provide a strong validation of our conjugation and soluble linker approaches and the data generated will be used to support the acquisition of additional financing this summer. Following funding, APTI will further optimize the linker technology while testing in additional ADC models to demonstrate the platform versatility and pursue ADC candidates for in-house clinical development.

https://www.advancedproteome.com/wp-content/uploads/2021/09/APC-Non-Confidential-Deck-Sep-2021.pdf

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities